SCHEMBL4141992

SCHEMBL4141992

COc1ccc(C(=O)Nc2ccccc2)c(OC)c1

nearest known ligand 0.75

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.75
MEN1 O00255 5/20 0.75
NPC1 O15118 4/20 0.75
RAB9A P51151 2/20 0.75
SMN1; SMN2 Q16637 4/20 0.68
POLB P06746 2/20 0.64
ALDH1A1 P00352 4/20 0.63
KCNK3 O14649 1/20 0.61
KCNK9 Q9NPC2 1/20 0.61
AKR1C3 P42330 1/20 0.61
MAPT P10636 2/20 0.60
HTT P42858 2/20 0.60
LMNA P02545 1/20 0.60
GAA P10253 1/20 0.59
PKM P14618 1/20 0.59
HPGD P15428 1/20 0.59
KLF5 Q13887 1/20 0.58
AHR P35869 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30786728 1.00 KMT2A (0.75) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL29627549 0.98 KMT2A (0.73) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL16149341 0.91 NPC1 (0.74) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL16148074 0.87 NPC1 (0.69) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL11648261 0.85 NPC1 (0.68) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL29771489 0.85 AKR1C3 (0.62) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL11582824 0.85 AKR1C3 (0.62) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL12468557 0.85 AVPR2 (0.75) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL14157012 0.84 NPC1 (0.66) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL7828380 0.84 NPC1 (0.62) KMT2AMEN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024013769-A1 PROCESS FOR SOLVENT FREE CONTINUOUS SYNTHESIS OF AMIDES AND PEPTIDES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2024-01-18 WO disclosed
WO-2024013769-A1 PROCESS FOR SOLVENT FREE CONTINUOUS SYNTHESIS OF AMIDES AND PEPTIDES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2024-01-18 WO disclosed
CN-101489988-A Process for alkenylation of carboxamides BASF AG (DE) 2009-07-22 CN disclosed
US-20090131657-A1 PROCESS FOR ALKENYLATING CARBOXAMIDES BASF SE (DE) 2009-05-21 US disclosed
US-4342875-A STABILIZERS FOR OLEFIN POLYMERS CINCINNATI-MILACRON, INC. (US) 1982-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131657-A1 PROCESS FOR ALKENYLATING CARBOXAMIDES PRMT5, CYC1, CBR3 KMT2A 41/4885MEN1 303/4885NPC1 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.